Product Information
XIFAXAN 200 MG TABLET is a brand product labeled by Salix Pharmaceuticals Inc., priced at $10.7162 per EA under NDC 65649030103. Its NADAC has been published 619 times since Nov 28, 2013.
FDA first approved this application on May 25, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Salix Pharmaceuticals Inc.NDC
65649030103
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
1/1/2025
Active Ingredients
RIFAXIMINApproval Type
New Drug (NDA)
FDA Application
NDA021361FDA Approved
5/25/2004
TE Code
AB
On Market Since
7/25/2004
Pharmacological Classes
Price Statistics
The NADAC for XIFAXAN 200 MG TABLET has been published 619 times since Nov 28, 2013, and over the history we have for it it has declined 18.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.7162 per EA |
|---|---|
| All-time high | $23.0267 (Oct 13, 2021) |
| All-time low | $9.2063 (Jan 12, 2022) |
| Median price | $15.4179 |
| Average price | $15.3141 |
| Largest weekly change | -60.0% (Jan 12, 2022) |
| Weeks tracked | 619 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+9.6%
5Y
-53.5%
All
-18.3%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the rifaximin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Salix Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rifaximin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Rifamycin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XIFAXAN 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for XIFAXAN 200 MG TABLET, manufactured by Salix Pharmaceuticals Inc., is $10.7162 per EA (NDC 65649030103), effective Oct 1, 2025.
How has the price of XIFAXAN 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for XIFAXAN 200 MG TABLET has declined 18.3%. It has been tracked across 619 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for XIFAXAN 200 MG TABLET?
Since Nov 28, 2013, the NADAC for XIFAXAN 200 MG TABLET has ranged from a low of $9.2063 (Jan 12, 2022) to a high of $23.0267 (Oct 13, 2021), with a median of $15.4179 per EA.
Are there cheaper alternatives to XIFAXAN 200 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of XIFAXAN 200 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XIFAXAN 200 MG TABLET?
XIFAXAN 200 MG TABLET (NDC 65649030103) is labeled by Salix Pharmaceuticals Inc., and CMS classifies it as a brand product.